Compare Match Group Inc (MTCH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Match Group Inc trades at $41.17 (market cap $9.53B), while State Street SPDR S&P Biotech ETF trades at $153.77 (market cap $10.11B). The key difference: Match Group Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and Match Group Inc pays a 1.93% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MTCH | XBI | |
|---|---|---|
Market Cap | $9.53B | $10.11B |
Volume | 3,228,794 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $44.40 | $169.55 |
52-Week Low | $28.90 | $104.99 |
Typical Hold Time | 115 Days | 38 Days |
Enterprise Value | $12.49B | — |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.48, up 1.52% today, near the consensus price target of $42.29. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentally, the company maintains robust profitability with a 20.17% net income margin and positive cash flow trends, while recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026. Positive sentiment is driven by product innovation at Tinder and growth from Hinge.
The outlook for MTCH is positive, supported by analyst consensus leaning buy (53% of ratings) and a projected EPS beat in Q3 2026. Investment opportunities include margin expansion and AI-driven product enhancements, but risks involve high debt levels and competitive pressures in the dating app market. Shareholder value may benefit from sustained cash flow generation and strategic initiatives.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
